Curis Lifesciences Ltd.

121.00-3.0 (-2.42%)

21 Aug, 12:00 AM

Income Statement

Abridged

Understanding Income Statement

Curis Lifesciences Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31
	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31
Period length: Source:	12M AR	12M PR	12M PR	12M PR	12M AR
Total Revenue	21.26	23.74	35.42	35.58	50.26
Cost of Operating Revenue	14.30	16.49	29.00	23.77	32.54
Gross Profit	6.96	7.25	6.42	11.81	17.72
Gross Margin	32.7	30.6	18.1	33.2	35.2
Total Operating Expenses	19.39	20.92	32.89	27.79	40.19
Operating Profit	1.87	2.82	2.53	7.78	10.07
Operating Margin	8.8	11.9	7.1	21.9	20.0
Financing Income/(Expense) - Net	-1.55	-1.62	-1.33	-0.90	-1.11
Profit before Taxes	0.56	1.23	2.17	7.20	8.99
Income Taxes	0.05	0.73	0.31	2.17	2.78
Profit after Tax	0.51	0.49	1.85	5.03	6.21
PAT Margin	2.4	2.1	5.2	14.1	12.3
EPS - Basic - ex Extraordinary Items	0.63	0.61	2.29	6.22	7.68
EPS - Diluted - ex Extraordinary Items	0.63	0.61	2.29	6.22	7.68
EBIT	1.87	2.82	2.53	7.78	10.07
EBITDA	2.57	3.58	3.25	8.46	10.74
EBITDA Margin	12.1	15.1	9.2	23.8	21.4

Balance Sheet

Abridged

Understanding Balance Sheet

Curis Lifesciences Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31
	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31
Source:	AR	PR	PR	PR	AR
Total Current Assets	12.50	14.88	17.29	22.05	31.35
Long-Term Investments	0.01	0.01	0.01	0.01	0.01
Property Plant & Equipment - Net	12.70	12.33	12.20	11.59	11.01
Total Non-Current Assets	13.55	12.52	12.37	11.77	11.24
Total Assets	26.05	27.40	29.67	33.82	42.60
Total Current Liabilities	11.91	15.81	18.54	18.17	17.39
Long Term Debt	15.55	12.41	9.78	8.70	7.50
Total Non-Current Liabilities	15.55	12.49	10.18	9.68	8.69
Total Liabilities	27.46	28.30	28.72	27.84	26.08
Total Shareholders' Equity	-1.41	-0.90	0.95	5.97	16.52
Total Equity	-1.41	-0.90	0.95	5.97	16.52
Total Liabilities & Equity	26.05	27.40	29.67	33.82	42.60

Cash Flow

Abridged

Understanding Cash Flow Statement

Curis Lifesciences Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31
	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31
Period length: Source:	12M PR	12M PR	12M PR	12M AR
Operating CF bef Changes in Working Cap	1.99	2.88	6.27	8.16
Working Capital - Increase/(Decrease)	1.35	-0.84	-6.83	-11.29
Net CF from Operating Activities	3.34	2.04	-0.56	-3.13
Capital Expenditures - Net	0.38	0.58	0.07	0.09
Net CF from Investing Activities	-0.38	-0.57	-0.07	-0.03
Stock - Issuance/(Retirement) - Net	-	-	-	4.25
Debt - LT & ST - Issuance/(Retirement) - Total	-2.96	-1.43	0.90	-1.20
Net Cash Flow from Financing Activities	-2.96	-1.43	0.90	3.05
Free Cash Flow to Equity	-0.01	0.03	0.26	-4.42
Free Operating CF net dividend	2.94	1.41	-0.63	-3.22
Free Operating CF	2.94	1.41	-0.63	-3.22

Business Segment Analysis

Curis Lifesciences Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

We don't have enough data to show business segment analysis for Curis Lifesciences Ltd.

Regional Segment Analysis

Curis Lifesciences Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Curis Lifesciences Ltd.

Historical Segment Analysis

Track how Curis Lifesciences Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

We don't have enough data to show segments for Curis Lifesciences Ltd.

Frequently Asked Questions

What is the revenue of Curis Lifesciences Ltd.?

The latest trailing twelve month revenue of Curis Lifesciences Ltd. is ₹ 50.26 Cr, reflecting a 1-year growth of 41.27% and a 3-year CAGR of 28.40%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Curis Lifesciences Ltd.?

The latest trailing twelve month net profit (PAT) of Curis Lifesciences Ltd. is ₹ 6.21 Cr, with a 3-year earnings CAGR of 132.73%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Curis Lifesciences Ltd.?

The trailing twelve month EBITDA of Curis Lifesciences Ltd. is approximately ₹ 10.07 Cr (based on an operating margin of 20.04%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Curis Lifesciences Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Curis Lifesciences Ltd. is 7.68. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Curis Lifesciences Ltd.?

The debt-to-equity ratio of Curis Lifesciences Ltd. stands at 0.95. The interest coverage ratio is 9.10x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Curis Lifesciences Ltd.?

The book value per share of Curis Lifesciences Ltd. is available in the Balance Sheet section of the Statements tab.

What is the cash flow from operations of Curis Lifesciences Ltd.?

The trailing twelve month operating cash flow of Curis Lifesciences Ltd. is ₹ -3.13 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Curis Lifesciences Ltd. report consolidated or standalone financials?

Curis Lifesciences Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.